Danone SA ADR Earnings Call: Growth, Cash, and Risks
Danone SA ADR ((DANOY)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Danone SA ADR’s latest earnings call struck an upbeat tone as management highlighted solid like-for-like sales growth, margin expansion, and robust cash generation despite clear regional and operational challenges. Executives framed infant milk formula recalls, North American weakness, and input cost pressures as manageable issues, emphasizing improved ROIC, rising EPS, and continued strategic execution as evidence of a resilient underlying story.
Steady Top-Line Expansion on a Like-for-Like Basis
Danone reported full-year like-for-like sales growth of 4.5%, with Q4 slightly stronger at 4.7% as both volume and mix contributed 2.7% for the year and 2.5% in the quarter. Pricing added 1.8% for the full year and 2.1% in Q4, while reported sales were broadly flat at EUR 27.3 billion after currency and scope effects dragged on headline growth.
Margins and EPS Edge Higher Toward Record Levels
Profitability continued to improve, with the recurring operating margin expanding by 44 basis points to 13.4% as cost discipline and mix improvements fed through. Recurring EPS rose 4.6% to EUR 3.80, putting earnings close to all-time highs and underscoring management’s focus on profitable growth rather than pure volume.
Cash Flow Strength Underpins Higher ROIC
The group generated EUR 2.8 billion of free cash flow in 2025, reinforcing its ability to fund growth investments, M&A, and shareholder returns. Return on invested capital moved firmly into double-digit territory at 10.7%, up about 62 basis points year-on-year, signalling better capital efficiency across the portfolio.
Broad-Based Category Momentum and Scaling Platforms
Specialized Nutrition led the way with 7.4% like-for-like growth, while the core Edible Dairy & Plant-based unit grew 3.5% and Waters advanced 1.9%. High-protein and plant-based platforms shone, with Oikos PRO surpassing EUR 1 billion in sales, Alpro joining the EUR 1 billion club, and Medical Nutrition brands Fortimel and Nutrison approaching the same scale.
Emerging Markets and CNAO Drive Regional Outperformance
China, North Asia and Oceania delivered standout like-for-like growth of 11.7%, almost entirely volume-driven at 12%, reflecting strong consumer demand and execution. Latin America and AMEA also contributed solidly with 6% and 5.6% like-for-like growth respectively, helping offset softer trends in more mature markets.
Strategic M&A Builds Medical Nutrition Scale
Danone used targeted deals to strengthen its higher-growth, higher-margin platforms, notably acquiring Kate Farms to build a meaningful U.S. Medical Nutrition presence of roughly $500 million in sales. The company also increased its stake in an Australian joint venture to 51%, gaining financial control and early evidence of scale benefits from integrating Kate Farms into its network.
Sustainability Credentials and Operational Excellence Recognized
The group highlighted its global B Corp certification and retention of CDP Triple A status as proof points of its environmental and social agenda. Operationally, Danone’s supply chain ranked 10th in Gartner’s Top 25 Supply Chains, while its Industry 5.0 Academy is upskilling 20,000 employees and piloting digital capabilities in 10 factories to raise efficiency and agility.
Dividend Growth Signals Confidence in Earnings Quality
Reflecting its earnings and cash-flow progress, Danone’s board will propose a dividend of EUR 2.25 per share, an increase of about 5% year-on-year. The payout rise roughly tracks EPS growth, suggesting management’s confidence that recent profitability improvements and cash generation are sustainable rather than one-off in nature.
Infant Milk Formula Recalls Weigh on Near-Term Sales
The company faced recalls of certain infant milk formula batches in Europe and the Middle East, causing shelf disruption and some consumer anxiety. Management estimates a one-off Q1 net sales impact of roughly 0.5% to 1.0% at group level, with most affected batches sold in 2025 and returns remaining limited so far.
North America Underperforms but Set for a Reboot
North America fell short of expectations, posting just 0.7% like-for-like growth in Q4, driven by price rather than volume, and only 2.0% growth for the full year. The region’s recurring operating margin declined by 39 basis points to 11%, prompting management to flag organizational and portfolio actions intended to restore momentum and profitability.
EDP Growth Solid but Margin Ambition Still Out of Reach
The Edible Dairy & Plant-based division is growing at 3.5% like-for-like but has yet to reach the targeted double-digit margin profile. Danone is deliberately reinvesting gross margin gains into innovation and competitiveness, banking on stronger, more sustainable growth rather than chasing short-term margin maximization.
FX, Scope and Ingredient Costs Pressure Reported Numbers
Currency translation shaved about 4.4% off sales and scope effects were slightly negative at 0.4%, as the deconsolidation of Horizon Organic was only partly offset by Kate Farms. In the second half, material cost inflation, especially in dairy ingredients like whey and lactose, combined with hedging timing, slowed the pace of gross margin expansion.
Managing Reputational Risk After IMF Recalls
While Danone noted no worrying trends in historical consumer complaints and early market-share data looks reassuring, the infant milk formula recalls carry a reputational risk that goes beyond Q1 numbers. The company is ramping up engagement with consumers and healthcare professionals to rebuild trust, but the ultimate long-term impact remains uncertain.
Guidance and Outlook Signal Confidence Beyond Near-Term Noise
For 2026, Danone is guiding for 3% to 5% like-for-like net sales growth and expects recurring operating income to grow faster than sales, indicating further margin ambition. Management acknowledged a one-off Q1 sales hit from formula recalls, but expects normalization by March, a Q2 recovery in North America as coffee-creamer comparisons ease, stepped-up capex at 4% to 4.5% of sales, and sustained double-digit ROIC alongside the higher dividend.
Danone’s earnings call painted a picture of a company balancing solid, broad-based growth and stronger financial metrics with tangible but contained risks from product recalls, North American softness, and cost pressures. For investors, the key takeaway is that strong cash flow, improving ROIC, and scaling high-value platforms underpin management’s confidence in delivering mid-single-digit growth and expanding profitability over the next phase.
